Hemoglobinopathies are a group of inherited blood disorders caused by abnormalities in hemoglobin, the protein inside red blood cells that carries oxygen throughout the body. More than 1,000 different hemoglobin disorders are known, and they collectively affect an estimated 2.1 billion people worldwide. The two most recognized forms are sickle cell disease and thalassemia, but dozens of other variants exist with a wide range of severity.
Two Main Categories
Hemoglobinopathies fall into two broad types based on what goes wrong with the hemoglobin molecule. In the first type, the body makes hemoglobin that has an abnormal structure. The protein itself is built incorrectly because of a change in the gene’s blueprint. Sickle cell disease is the most common example: a single amino acid swap in one of hemoglobin’s building blocks produces a defective molecule that distorts the shape of red blood cells.
In the second type, the hemoglobin structure is normal, but the body doesn’t produce enough of one of its components. These are called thalassemias. Red blood cells end up with an imbalance of their protein chains, which makes them fragile and prone to breaking apart. Think of it this way: structural variants are a quality problem, while thalassemias are a quantity problem. Some people inherit genes for both types at once, creating overlap conditions that can be more complex to manage.
How Sickle Cell Disease Works
Sickle cell disease is the most well-known hemoglobinopathy. It occurs when a person inherits two copies of the gene for hemoglobin S, one from each parent. The mutation swaps a single building block in the hemoglobin chain, replacing a negatively charged amino acid (glutamate) with a neutral one (valine). That small change has outsized consequences.
When oxygen levels drop, the altered hemoglobin molecules lock together into rigid, rod-like structures. This forces red blood cells out of their normal disc shape into a crescent or “sickle” shape. Early on, the process is reversible: cells sickle when oxygen is low and return to normal when oxygen rises again. Over time, though, repeated cycles of sickling cause permanent damage to the cell membrane, and the cells stay misshapen.
These stiff, sticky cells can block small blood vessels, triggering what’s called a vaso-occlusive crisis. People describe the pain as sharp, intense, stabbing, or throbbing. It can hit the abdomen, chest, lower back, or limbs, often in more than one area at once, and it can come on without warning. Beyond pain episodes, sickle cell disease gradually damages organs. The spleen is especially vulnerable because sickle cells get trapped there, causing it to enlarge and lose its ability to fight certain infections. Over time, kidney scarring can lead to kidney failure, and the disease raises the risk of stroke, lung complications, and chronic fatigue from ongoing anemia.
Alpha and Beta Thalassemia
Thalassemias are named for whichever hemoglobin chain is underproduced. Alpha thalassemia results from reduced or absent production of alpha globin chains. Beta thalassemia involves the same problem with beta globin chains. In both cases, the imbalance between chain types damages developing red blood cells and shortens their lifespan.
Severity varies dramatically depending on how many genes are affected. Silent carriers of alpha thalassemia and people with either alpha or beta thalassemia trait typically have no symptoms and need no treatment. They may never know they carry the gene unless they’re tested. On the more serious end, beta thalassemia major causes significant anemia, poor growth, and skeletal changes in infancy. Children with this condition require regular blood transfusions for life. Beta thalassemia intermedia falls in between and may need transfusions only during illness or growth spurts.
Alpha thalassemia has its own spectrum. Hemoglobin H disease (alpha thalassemia intermedia) causes moderate hemolytic anemia. The most severe form, alpha thalassemia major, produces a type of hemoglobin called Bart’s that cannot deliver oxygen effectively. It is almost always fatal before or shortly after birth.
Less Common Variants
Beyond sickle cell and thalassemia, several other hemoglobin variants are worth knowing about. Hemoglobin C disease, found in about 2 to 3 percent of African Americans, generally causes only mild anemia that rarely interferes with daily life, though some people develop an enlarged spleen or gallstones. Hemoglobin E is the second most common variant globally after hemoglobin S and is especially prevalent in Southeast Asia, where carrier rates reach 30 to 40 percent in parts of Thailand, Cambodia, and Laos. On its own, hemoglobin E disease causes mild anemia and usually requires no treatment. However, when hemoglobin E is inherited alongside a beta thalassemia gene, the combination can produce a condition as severe as beta thalassemia major.
Who Is Most Affected
Hemoglobinopathies are not evenly distributed around the world. They are most common in populations from sub-Saharan Africa, the Mediterranean, the Middle East, India, and Southeast Asia. This geographic pattern is not random. Carrying one copy of certain hemoglobin variant genes (being a “trait” carrier) offers some protection against malaria, so these genes became more common in regions where malaria has historically been widespread.
The numbers are staggering. An estimated 515,000 babies are born with sickle cell disease each year worldwide, with the WHO African Region accounting for roughly 20 percent of the global hemoglobinopathy burden (about 425.8 million people). Alpha thalassemia affects approximately 5 percent of the world’s population, while beta thalassemia affects about 1.5 percent, or 80 to 90 million people.
How Hemoglobinopathies Are Detected
Most hemoglobinopathies are identified through newborn screening, which is standard practice in many countries. The two most common initial screening methods are isoelectric focusing (IEF) and high-performance liquid chromatography (HPLC), both of which separate different types of hemoglobin in a blood sample so abnormal variants can be identified. Some programs add molecular (DNA-based) testing as a second step to confirm or clarify results.
For older children and adults, hemoglobin electrophoresis is the standard diagnostic tool. It works by applying an electrical charge to a blood sample, causing different hemoglobin types to migrate at different speeds. The resulting pattern reveals whether hemoglobin S, C, E, or other variants are present, and in what proportions. A complete blood count and iron studies are usually done alongside electrophoresis to distinguish hemoglobinopathies from iron deficiency and other causes of anemia.
Complications of Long-Term Treatment
For people with severe forms of thalassemia or sickle cell disease who need regular blood transfusions, iron overload is the most serious treatment-related complication. The body has no natural way to eliminate excess iron, and each unit of transfused blood delivers a significant iron load. Without intervention, that iron accumulates in the heart, liver, and hormone-producing glands.
The consequences develop over years. Iron deposits in the heart can cause heart failure, sometimes as early as a person’s teens or twenties. In the liver, excess iron leads to scarring (fibrosis) and eventually cirrhosis, with an increased risk of liver cancer. Iron also damages the pituitary gland, which can delay puberty, stunt growth, and cause hormonal imbalances including thyroid problems and diabetes. To prevent this, people on regular transfusions take iron chelation therapy: medications that bind excess iron so the body can excrete it. Three chelation drugs are currently available, including one given by injection under the skin and two taken by mouth as tablets.
Gene Therapy as a Newer Option
In December 2023, the FDA approved the first two gene therapies for sickle cell disease, marking a turning point in treatment. One therapy, Casgevy, uses CRISPR gene-editing technology to modify a patient’s own blood stem cells. The edit boosts production of fetal hemoglobin, a form of hemoglobin that healthy babies naturally produce but that normally decreases after birth. Higher levels of fetal hemoglobin prevent red blood cells from sickling. In clinical trials, 29 out of 31 evaluable patients (93.5 percent) went at least 12 consecutive months without a severe pain crisis after treatment.
The second therapy, Lyfgenia, uses a different approach. It inserts a new gene into stem cells using a viral delivery vehicle, prompting the cells to produce a modified hemoglobin that functions like normal adult hemoglobin. In trials, 88 percent of patients achieved complete resolution of pain crises in the year following treatment. Both therapies require a one-time procedure, but the process is intensive: patients first undergo chemotherapy to clear space in the bone marrow, then receive the modified stem cells through an infusion similar to a bone marrow transplant. Recovery takes weeks to months in a hospital setting.
These gene therapies represent the closest thing to a cure currently available for sickle cell disease. Bone marrow transplants from matched donors have been another curative option for years, but finding a suitable donor is a major barrier for many patients. Gene therapy sidesteps that problem by using the patient’s own cells.